Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice

British Journal of Haematology

Volumn 102, Issue 2, 1998, Pages 522-527

  Clutterbuck, Robyn D ^a   Millar, Barbara C ^a   Powles, Ray L ^a   Newman, Ann ^a   Catovsky, Daniel ^a   Jarman, Michael ^a   Millar, John L ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Human leukaemia; SCID mice; Simvastatin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; SIMVASTATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DRUG EFFECT; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ACUTE DISEASE; ANIMALS; CELL DIVISION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKEMIA, MYELOID; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; SIMVASTATIN;

EID: 0031871164     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00783.x     Document Type: Article

References (33)

1. Bos, J.L., Verlan de Vries, M., van der Eb, A.J., Janssen, J.W.G., Delwel, R., Lowenberg, B. & Colly, L.P. (1987) Mutations in N-ras predominate in acute myeloid leukemia. Blood, 69, 1237-1241.
2. Bradley, T.R., Hodgson, G.S. & Rosendaal, M. (1978) The effect of oxygen tension on haemopoietic and fibroblast cell proliferation in vitro. Journal of Cellular Physiology, 97, 517-522.
3. Buchwald, H. (1992) Cholesterol inhibition, cancer and chemotherapy. Lancet, 339, 1154-1156.
4. Collins, S. & Groudine, M. (1982) Amplification of endogenous mycrelated DNA sequences in a human myeloid leukaemia cell line. Nature, 298, 679-681.
5. Dricu, A., Wang, M., Hjertman, M., Malec, M., Blegen, H., Wejde, J., Carlberg, M. & Larsson, O. (1997) Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. Glycobiology, 7, 625-633.
6. Gibbs, J.B., Oliff, A. & Kohl, N.E. (1994) Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell, 77, 175-178.
7. Girgert, R., Marini, P., Janessa, A., Bruchelt, G., Treuner, J. & Schweizer, P. (1994) Inhibition of the membrane localisation of p21 ras proteins by lovastatin in tumor cells possessing a mutated N-ras gene. Oncology, 51, 320-322.
8. Hancock, J.F., Paterson, H. & Marshall, C.J. (1990) A polybasic domain or palmitoylation is required in addition to the CAAX motif to localise p21ras to the plasma membrane. Cell, 63, 133-139.
9. Imaizumi, M. & Breitman, T.R. (1988) Changes in c-myc, c-fms, and N-ras proto-oncogene expression associated with retinoic acid-induced monocytic differentiation of human leukaemia HL60/MRI cells. Cancer Research, 48, 6733-6738.
10. Jani, J.P., Specht, S., Stemmler, N., Blanock, K., Singh, S.V., Gupta, V. & Katoh, A. (1993) Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion and Metastasis, 13, 314-324.
11. Kawata, S., Kakimoto, L.H., Ishiguro, H., Yamasaki, E., Inui, Y. & Matsuzawa, Y. (1992) Effect of pravastatin, a potent 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, on survival of AH1 30 hepatoma-bearing rats. Japanese Journal of Cancer Research, 83, 1120-1123.
12. Kita, T., Brown, M.S. & Goldstein, J.L. (1980) Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. Journal of Clinical Investigation, 66, 1094-1100.
13. Kohl, N.E., Mosser, S.D., deSolms, J., Giuliani, E.A., Pompliano, D.L., Graham, S.L., Smith, R.L., Scolnick, E.M., Oliff, A. & Gibbs, J.B. (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science, 260, 1934-1937.
14. Larsson, O. (1996) HMG-CoA reductase inhibitors: role in normal and malignant cells. Critical Reviews in Oncology/Haematology, 22, 197-212.
15. Lehninger, A.L. (1975) Biochemistry, 2nd edn. Worth, New York.
16. Mitchell, P.L.R., Clutterbuck, R.D., Powles, R.L., De Lord, C., Morilla, R., Hiorns, L.R., Titley, J., Catovsky, D. & Millar, J.I., (1996) Interleukin-4 enhances the survival of severe combined immunodeficient mice engrafted with human B-cell precursor leukemia. Blood, 87, 4797-4803.
17. Newman, A., Clutterbuck, R.D., DeLord, C., Powles, R.L., Catovsky, D. & Millar, J.L. (1995) The sensitivity of leukaemia bone marrow to simvastatin is lost at remission: a potential purging agent for autologous bone marrow transplantation. Journal of Investigative Medicine, 43, 269-274.
18. Newman, A., Clutterbuck, R.D., Powles, R.L., Catovsky, D. & Millar, J.L. (1997) A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leukemia and Lymphoma, 24, 533-537.
19. Newman, A., Clutterbuck, R.D., Powles, R.L. & Millar, J.L. (1994) Selective inhibition of primary acute myeloid leukemia cell growth by simvastatin. Leukemia, 8, 2023-2029.
20. Pentikainen, P.J., Saraheimo, M., Schwartz, J.I., Amin, R.D., Schwartz, M.S., Brunner-Ferber, F. & Rogers, J.D. (1992) Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. Journal of Clinical Pharmacology, 32, 136-140.
21. Pizer, E.S., Wood, F.D., Pasternack, G.R. & Kuhajda, F.P. (1996) Fatty acid synthesis (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Research, 56, 745-751.
22. Powles, R., Lister, T.A., Oliver, R.T.D., Russell, J., Smith, C., Kay, H.E.M., McElwain, T.J. & Hamilton-Fairley, G. (1974) Safe method for collecting leukaemia cells from patients with acute myeloid leukaemia for use as immunotherapy. British Medical Journal, iv, 375-379.
23. ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell, 62, 81-88.
24. Rowe-Jones, D.C. (1969) Cytotoxic penetration and concentration in human malignant tumours. British Journal of Surgery, 56, 774-778.
25. Sebti, S.M., Tkalcevic, G.T. & Jani, J.P. (1991) Lovastatin, a cholesterol biosynthetic inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Communications, 3, 141-147.
26. Siperstein, M.D. (1984) Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. Journal of Lipid Research, 25, 1462-1468.
27. Suzuki, M., Hori, K., Abe, I., Saito, S. & Sato, H. (1981) A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin. Journal of the National Cancer Institute, 67, 663-669.
28. Thibault, A., Samid, D., Tompkins, A.C., Figg, W.D., Cooper, M.R., Hohl, R.J., Trepel, J., Liang, B., Patronas, N., Venzon, D.J., Reed, E. & Myers, C.E. (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clinical Cancer Research, 2, 483-491.
29. Toksoz, D., Farr, C.J. & Marshall, C.J. (1989) Ras genes and acute myeloid leukaemia. British Journal of Haematology, 71, 1-6.
30. Trzaskos, J.M., Fischer, R.T. & Favata, MF. (1986) Mechanistic studies of lanosterol C-32 demethylation. Journal of Biological Chemistry, 261, 16937-16942.
31. Vitols, S., Angeli, B. & Juliusson, G. (1997) Simvastatin impairs milogen-induced proliferation of malignant B-lymphocytes from humans: in vitro and in vivo studies. Lipids, 32, 255-262.
32. Wilkinson, J., 4th, Cerda, S., Cerda, S.R., Branch, S.K. & Broitman, S.A. (1995) Limonene (LE) and mevinolin (MV) affect growth of the human colonic adenoCA LS174T implanted in the livers of nude mice. (Abstract). Proceedings of the Annual Meeting of the American Association of Cancer Research, 36, A1776.
33. Zar, J.H. (1984) Biostatistical Analysis, 2nd edn. Prentice-Hall, New Jersey.